Abiopharma

🔍 Danahy Kevin Patrick (Executive)

Company: PULSE BIOSCIENCES, INC. (PLSE)

Report Date: 2026-02-09

Detailed Transactions and Holdings:

• Acquired 20,000 shares of Common Stock at $1.53 per share (Direct)
  Date: 2026-02-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 63,298.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 20,000 shares of Common Stock at $21.45 per share (Direct)
  Date: 2026-02-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 43,298.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 20,000 shares of Common Stock at $1.53 per share (Direct)
  Date: 2026-02-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 63,298.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 20,000 shares of Common Stock at $23.52 per share (Direct)
  Date: 2026-02-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 43,298.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Acquired 20,000 shares of Common Stock at $1.53 per share (Direct)
  Date: 2026-02-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 63,298.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 20,000 shares of Common Stock at $25.2 per share (Direct)
  Date: 2026-02-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 43,298.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 20,000 shares of Stock Option (right to buy) at $1.53 per share (Derivative)
  Date: 2026-02-09 | Code: M | Expires: 2032-09-23 | equity_swap_involved: 0 | shares_owned_after: 405,000.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 20,000 shares of Stock Option (right to buy) at $1.53 per share (Derivative)
  Date: 2026-02-10 | Code: M | Expires: 2032-09-23 | equity_swap_involved: 0 | shares_owned_after: 385,000.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 20,000 shares of Stock Option (right to buy) at $1.53 per share (Derivative)
  Date: 2026-02-11 | Code: M | Expires: 2032-09-23 | equity_swap_involved: 0 | shares_owned_after: 365,000.00 | transaction_form_type: 4 | Footnotes: F1, F5

Footnotes:

• F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.
• F2: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $21.00 to $23.22 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.
• F3: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $23.00 to $26.08 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.
• F4: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $23.36 to $26.36 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.
• F5: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022.